The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance.
about
Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importanceBile acid receptors and nonalcoholic fatty liver diseaseBile acid signaling in metabolic disease and drug therapyThe human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract.Pharmacological activation of the bile acid nuclear farnesoid X receptor is feasible in patients with quiescent Crohn's colitis.Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease.Low vitamin D status is associated with nonalcoholic Fatty liver disease independent of visceral obesity in Korean adults.Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease.Enterohepatic bacterial infections dysregulate the FGF15-FGFR4 endocrine axis.Serum concentrations of fibroblast growth factors 19 and 21 in women with gestational diabetes mellitus: association with insulin resistance, adiponectin, and polycystic ovary syndrome history.Bile Acid Metabolome after an Oral Lipid Tolerance Test by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).Fibroblast Growth Factor Signaling Controls Liver Size in Mice With Humanized LiversBile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease.Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic DiseasesActivation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor β-Klotho.A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass.MicroRNA-34a and Impaired FGF19/21 Signaling in ObesityCholic acid therapy in Zellweger spectrum disorders.The portal-drained viscera release fibroblast growth factor 19 in humans.Prolonged fibroblast growth factor 19 response in patients with primary sclerosing cholangitis after an oral chenodeoxycholic acid challenge.Up-regulation of fibroblast growth factor 19 and its receptor associates with progression from fatty liver to hepatocellular carcinoma.Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease.Farnesoid x receptor agonists: what they are and how they might be used in treating liver disease.Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liver.Bile acid receptors as targets for drug development.Targeting fibroblast growth factor 19 in liver disease: a potential biomarker and therapeutic target.Farnesoid x receptor in human metabolism and disease: the interplay between gene polymorphisms, clinical phenotypes and disease susceptibility.Fibroblast growth factor 19-targeted therapies for the treatment of metabolic disease.FXR agonists as therapeutic agents for non-alcoholic fatty liver disease.Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification.FGF19: How gut talks to brain to keep your sugar down.Central action of FGF19 reduces hypothalamic AGRP/NPY neuron activity and improves glucose metabolism.Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis.Novel associations of bile acid diarrhoea with fatty liver disease and gallstones: a cohort retrospective analysis.Relationship of non-alcoholic fatty liver disease with cholecystectomy in the US population.Laparoscopic sleeve gastrectomy differentially affects serum concentrations of FGF-19 and FGF-21 in morbidly obese subjects.Enhanced fasting and post-prandial plasma bile acid responses after Roux-en-Y gastric bypass surgery.
P2860
Q26769609-77DDB7C2-B3B6-4874-B51B-819DED50038CQ26775814-C5B7DB5E-4D43-4437-9A8E-076A62723D3CQ28244875-B4E8CE81-D0DD-4974-9106-3CE4610DF367Q34219880-81DAE7EC-E632-4D79-A8F2-BD5A2D23B042Q34493836-4E3D0F77-BB06-4125-A83B-F8B118B93A20Q34806589-4D258717-6D4C-45B5-8A72-730C4CCD72AFQ35018209-16A696F6-E47B-405A-93BA-E62905289EBAQ35020888-7AD8DA51-6768-40F0-86F5-011EF02BE014Q35027404-F8676B21-389B-441B-96BA-4F331CC0286EQ35049496-6A52D132-EB37-4613-9D13-89DB8CEF334DQ35919570-723F04F5-DD61-4CFC-A775-C59AD5BB1AD8Q35998475-2D17D6D7-955D-48B3-8654-16D1C8856074Q36023779-FCC09802-3718-4DF1-B04B-139F51240A59Q36107291-6ACE9E47-7583-4A24-BA90-C24BCE2D9FBAQ36127237-E552130E-057D-4E58-9BE7-AF335DD9127EQ36342875-BF016074-0FA2-43A8-B0C6-3074F217B97AQ36942098-4D44FDD5-706E-4E7F-BFEF-601CA7B08B1CQ37160100-F0B8A166-00A3-4E81-BBF0-95D96D212A24Q37341914-C5FD1801-22C6-4671-A5D8-8F47FE4C8655Q37556251-100D5B84-2E53-4E4D-9002-BCE18BED14F7Q37584099-4E830480-0828-4220-8E51-EB0F07B24843Q37588455-A3B7C14F-8884-437C-B4C4-B8F7E67B8040Q37781747-2621973D-BF32-4C25-B382-1FDCB2C37876Q37957663-B7223184-9EF7-4526-A20B-C6A6D18B7933Q38023300-F26BA65E-593D-4453-95A8-37879DF886A3Q38132058-0D883E0F-F263-4A90-9A3C-37E91838EBD8Q38303270-DF49531D-F071-4E28-89C5-6C9031657B66Q38305576-7B80D625-974D-40E4-A439-1B7B53D30DF9Q38325739-4EE09BBD-5BF5-427A-B475-37A12DAAECD1Q38359118-6C4E0510-A149-4D7F-9351-04137E421E27Q38633258-61BC0C48-3B33-4753-A738-B5DBC8DD5BDEQ39262148-593717CE-85AF-4CB5-AAD5-B0DF09664813Q39363389-C970AF0B-FCA0-4146-BAB8-AFA63CD24131Q41826321-89BFB8F1-1C1E-47F1-89E4-94E5429B9CCEQ41959673-4305F135-DFAE-4FE7-AFBC-3BC31D45B067Q42367659-4C236A5F-F1AC-41D0-B3A1-FA619A91CE5CQ43270593-279B8C2D-97E7-4109-A4AD-525A8DB82389Q43614017-8BFD561E-8912-4146-AF9A-46720361A795Q44427743-111F9D34-D731-4E08-9136-0CB0F1887119Q44581393-393CCE55-373E-4581-A3C9-F6AC60EE1ED4
P2860
The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The hepatic response to FGF19 ...... isease and insulin resistance.
@ast
The hepatic response to FGF19 ...... isease and insulin resistance.
@en
The hepatic response to FGF19 ...... isease and insulin resistance.
@nl
type
label
The hepatic response to FGF19 ...... isease and insulin resistance.
@ast
The hepatic response to FGF19 ...... isease and insulin resistance.
@en
The hepatic response to FGF19 ...... isease and insulin resistance.
@nl
prefLabel
The hepatic response to FGF19 ...... isease and insulin resistance.
@ast
The hepatic response to FGF19 ...... isease and insulin resistance.
@en
The hepatic response to FGF19 ...... isease and insulin resistance.
@nl
P2093
P2860
P356
P1476
The hepatic response to FGF19 ...... disease and insulin resistance
@en
P2093
Aart J Nederveen
Hendrik A Marsman
Jochem R van Werven
Peter L M Jansen
Tim C M A Schreuder
P2860
P304
P356
10.1152/AJPGI.00322.2009
P577
2010-01-21T00:00:00Z